---
title: "Insilico Medicine Subsidiary Partners With Luoxin Pharmaceuticals on AI-Powered Drug Discovery"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305433887.md"
description: "Insilico Medicine Ltd., a subsidiary of Insilico Medicine Cayman TopCo, has entered a strategic collaboration with Luoxin Pharmaceuticals. The partnership focuses on AI-powered drug discovery for digestive, metabolic, and other non-oncology chronic diseases. Specific projects are subject to negotiation and definitive agreements, with implementation planned in phases."
datetime: "2026-11-13T08:36:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305433887.md)
  - [en](https://longbridge.com/en/news/305433887.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305433887.md)
generator: "portal-rs"
---

# Insilico Medicine Subsidiary Partners With Luoxin Pharmaceuticals on AI-Powered Drug Discovery

-   Insilico Medicine Cayman TopCo’s wholly owned subsidiary, Insilico Medicine Ltd., entered a strategic drug-discovery collaboration with Luoxin Pharmaceuticals. \* The partnership will prioritize AI-powered research into digestive, metabolic and other non-oncology chronic diseases. \* Specific projects remain subject to negotiation and definitive agreements, with implementation planned in phases. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261113-12411853), on November 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [03696.HK](https://longbridge.com/en/quote/03696.HK.md)
- [002793.CN](https://longbridge.com/en/quote/002793.CN.md)

## Related News & Research

- [InSilico Medicine Hits Early AI Drug Discovery Milestone in Servier Collaboration](https://longbridge.com/en/news/302341377.md)
- [Insilico Medicine Reports 40% Response Rate at 130 mg for ISM6331 in Phase 1 Mesothelioma Trial](https://longbridge.com/en/news/303086760.md)
- [InSilico Medicine Advances AI‑Designed Autoimmune Drug Candidate ISM9546](https://longbridge.com/en/news/301636198.md)
- [Chainfir Capital says AI drug deal headlines mask reliance on uncertain milestone payments](https://longbridge.com/en/news/302495363.md)
- [AI-Driven Drug Development Enters Validation Phase; Talent Competition Intensifies](https://longbridge.com/en/news/297476845.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**